USD 500k annual excess billing controlled at a leading dermatology clinic after 16 Mohs surgeries on one patient in 18 months

Case 3 · Provider Level · Asia-Pacific

WHERE WE STARTED

A blue-chip dermatology clinic in the Asia-Pacific region was billing for Mohs micrographic surgery at a rate that looked unremarkable in any single claim. Mohs is a highly specialised, high-cost procedure used to remove skin cancer in precise tissue layers — and at this clinic, it was presented as the gold standard of care. The insurer had long-standing suspicions but no evidence. The billing was within contractual terms, so the existing rules engine never triggered.

THE CHALLENGE

Mohs surgery is rarely repeated on the same site within a short interval — the procedure is designed to achieve clear margins in as few sessions as possible, and repeat procedures within weeks raise serious clinical questions about both necessity and technique. Yet the clinic continued to bill at high volumes, and every claim was technically compliant.

What had already been tried:

Because the billing fell within contract parameters, the insurer’s standard fraud controls passed everything through. The clinical team lacked the analytical tools to compare this provider’s Mohs billing rate against population norms, or to assess whether the gap between repeat procedures on the same patient was clinically appropriate. Without that benchmark, there was no basis for challenge — and the clinic knew it.

HOW KIRONTECH FOUND IT

HIP rated surgical procedures on a complexity ladder and linked each to clinical necessity and likelihood scores.
Units of Mohs surgery per patient at this clinic were identified as significantly out of line with population norms — one patient had undergone 16 Mohs interventions in 18 months.
HIP flagged that the gap between repeated Mohs procedures on the same site was shorter than clinical guidelines recommend, raising questions about both clinical justification and patient safety.
Excessive cryotherapy — a high-cost, high-frequency freezing treatment used for skin lesions — was identified as a further anomaly, with volumes inconsistent with expected clinical need.
Three independent signals converging on the same provider formed a data-backed case for contract review that the insurer had never previously been able to build.

Insurer challenge

Outcome & impact

The clinic was a respected name; Mohs surgery was presented as its gold standard — internal resistance to challenge was high. All billing fell within contractual terms, meaning the rules engine had no grounds to flag it. The insurer had long suspected the clinic but had struggled to build an evidence base without benchmark data.

Data and findings used to renegotiate the clinic’s contract — the clinic disputed the findings and pushed back significantly before ultimately accepting the evidence. Patient safety audit conducted on the 16 Mohs procedures — audit confirmed the procedures were clinically unjustified. Excess billing controlled at USD 500k per annum. A precedent established for data-led provider renegotiation across the insurer’s network.

WHAT CHANGED

The shift here was cultural as much as financial. For the first time, the insurer’s contract management team could enter a provider negotiation with hard comparative data rather than suspicion — and sustain that position under challenge. The renegotiated contract introduced procedure frequency caps backed by clinical evidence — a template now applied to other high-billing specialists in the network.

THE RESULT

Excess billing identified and controlled at USD 500k per annum. Contract renegotiated using data as evidence — after significant clinic pushback. Patient safety audit confirmed 16 Mohs procedures on one patient were clinically unjustified.

USD 500k annual excess billing controlled at a leading dermatology clinic after 16 Mohs surgeries on one patient in 18 months

Expertise and insight

Start your medical claims and payment risk intelligence journey